Anti-ROR1 antibodies
AssigneeEureka Therapeutics, Inc.
InventorsBrian Wong, Emma Masteller, Cheng Liu, Yiyang Xu, Hong Liu, Su Yan, Jingyi Xiang, Pei Wang
Life of this patent
Estimating the term…
Abstract
The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.
Claims13
An isolated human anti-Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) antibody or an antigen binding fragment thereof that binds to the ROR1 protein set forth in SEQ ID NO:
- 2, wherein the antibody or antigen binding fragment thereof comprises at least one antigen binding region comprising light chain complementary determining region (LCDR) amino acid sequences set forth in SEQ ID NOs:
- 309, 310, and 311 and heavy chain complementary determining region (HCDR) amino acid sequences set forth in SEQ ID NOs:
- 410, 411, and 412.
Dependencies are inferred from the claim text.